Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study

BACKGROUND: Fimasartan is a novel angiotensin II receptor blocker. Fimasartan is mainly eliminated via biliary excretion, and its urinary elimination is less than 3%. OBJECTIVE: Based on guidance from the United States Food and Drug Administration, a reduced pharmacokinetic (PK) study was conducted...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kim, Seokuee, Lee, Jongtae, Shin, Donghoon, Lim, Kyoung Soo, Kim, Yon Su, Jang, In-Jin, Yu, Kyung-Sang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2014
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199969/
https://ncbi.nlm.nih.gov/pubmed/25336916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S68784
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller